# Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Source: https://onco.cc/trials/nct05287113/  
OnCo record `nct05287113` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Retifanlimab in head and neck squamous cell carcinoma, run by Incyte Biosciences International Sàrl, active and no longer recruiting.

## Summary

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck is a phase 2 interventional study registered as NCT05287113 by Incyte Biosciences International Sàrl, with 176 participants enrolled, started 2022-11-14 and due to reach its primary completion in 2025-03-14. Interventions recorded: Retifanlimab, INCAGN02385, INCAGN02390 and Placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05287113
- Phase: 2
- Setting: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Sponsor: Incyte Biosciences International Sàrl
- Enrolled: 176

## Sources

- ClinicalTrials.gov NCT05287113: https://clinicaltrials.gov/study/NCT05287113

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Retifanlimab](https://onco.cc/drugs/retifanlimab/)

---
JSON: https://onco.cc/api/v1/entities/nct05287113.json